Nuklearmedizin 2019; 58(02): 109
DOI: 10.1055/s-0039-1683483
Wissenschaftliches Programm: Leuchtturm-Sitzungen
Leuchtturm-Sitzung 3: Uroonkologie
Georg Thieme Verlag KG Stuttgart · New York

Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA

B Feuerecker
1   Klinikum rechts der Isar, Nuklearmedizinische Klinik und Poliklinik, München
,
K Knorr
1   Klinikum rechts der Isar, Nuklearmedizinische Klinik und Poliklinik, München
,
A Beheshti
1   Klinikum rechts der Isar, Nuklearmedizinische Klinik und Poliklinik, München
,
C Seidl
1   Klinikum rechts der Isar, Nuklearmedizinische Klinik und Poliklinik, München
,
C D'Alessandria
1   Klinikum rechts der Isar, Nuklearmedizinische Klinik und Poliklinik, München
,
F Bruchertseifer
2   European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe
,
R Tauber
3   Klinikum rechts der Isar, Urologische Klinik und Poliklinik, München
,
M Retz
3   Klinikum rechts der Isar, Urologische Klinik und Poliklinik, München
,
W Weber
1   Klinikum rechts der Isar, Nuklearmedizinische Klinik und Poliklinik, München
,
A Morgenstern
2   European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe
,
M Eiber
1   Klinikum rechts der Isar, Nuklearmedizinische Klinik und Poliklinik, München
› Author Affiliations
Further Information

Publication History

Publication Date:
27 March 2019 (online)

 

Ziel/Aim:

Despite the approval of several new agents metastatic castration resistant prostate cancer is still a major medical challenge. The beta-emitting Lu-177-PSMA radioligand therapy (RLT) is a new option but its antitumor effect can decrease over time. The aim of this retrospective analysis was to investigate safety and efficacy of the alpha emitting Ac-225-PSMA-617 RLT in mCRPC after Lu-177-PSMA failure.

Methodik/Methods:

15 patients underwent Ac-225-PSMA-617 RLT between 10/17 and 08/18. All patients had previously received second line antihormonal treatment, as well as chemotherapy and had shown progression after Lu-177-PSMA therapy (median 2 cycles). Repeat PSMA-PET/CT before Ac-225-PSMA-617 therapy indicated continued high PSMA-expression. Patients were treated at 8 weekly intervals until progression or intolerable side effects. Prostate-specific antigen (PSA) and blood cell count were measured every 2 – 3 weeks. We report hematological and non-hematological side effects (Common Terminology Criteria for Adverse Events) and biochemical response.

Ergebnisse/Results:

A total of 27 cycles of Ac-225-PSMA-617 (median dose 8 MBq, range 6 – 12.8) were applied. 5 patients received only 1 cycle, 8 patients 2 cycles and 2 patients 3 cycles. Baseline PSA was 758 ng/ml (range 49 – 4073). ECOG score was grade 0, 1 and 2 in 3, 10 and 2 patients, respectively. 10/15 patients showed any PSA-decline, 5/15 a PSA-decline of more than 50% and 3 patients no PSA-decline at any time. Grade 1 – 2 xerostomia occurred in 14 and 1 patient, respectively. 5/15 patients requested to stop treatment due to xerostomia. Two patients developed grade 2 renal insufficiency, 4 patients grade 3 – 4 anemia, 2 patients grade 3 thrombocytopenia. No grade 3 – 4 leucopenia was observed. 7/15 patients died during the observation period (median overall survival 8 months).

Schlussfolgerungen/Conclusions:

In this small cohort Ac-225-PSMA-617 RLT showed antitumor effect in mCRPC after Lu-177-PSMA failure. However, treatment had to be stopped in one third of the patients due to xerostomia.